v3.22.2.2
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Oct. 02, 2022
Oct. 03, 2021
Oct. 02, 2022
Oct. 03, 2021
Restructuring Reserve [Roll Forward]        
Balance, beginning [1]     $ 1,071  
Provision [2] $ 177 $ 643 368 $ 656
Utilization and other [3]     (572)  
Balance, ending [4] 867   867  
Other Current Liabilities [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning     816  
Balance, ending 758   758  
Other Noncurrent Liabilities [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning     255  
Balance, ending 110   110  
Employee Termination Costs [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning [1]     1,014  
Provision     293  
Utilization and other [3]     (447)  
Balance, ending [4] 859   859  
Asset Impairment Charges [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning [1]     0  
Provision     44  
Utilization and other [3]     (44)  
Balance, ending [4] 0   0  
Exit Costs [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning [1]     57  
Provision     31  
Utilization and other [3]     (80)  
Balance, ending [4] $ 8   $ 8  
[1] Included in Other current liabilities ($816 million) and Other noncurrent liabilities ($255 million).
[2] Primarily represents cost reduction initiatives. Restructuring charges/(credits) associated with Biopharma: charges of $62 million and $108 million for the three and nine months ended October 2, 2022, respectively, and charges of $616 million and $617 million for the three and nine months ended October 3, 2021, respectively.
[3] Includes adjustments for foreign currency translation.
[4] Included in Other current liabilities ($758 million) and Other noncurrent liabilities ($110 million).